Tandem Diabetes Care 

$20.09
71
+$0.2+1.01% Monday 21:00

Statistics

Day High
20.96
Day Low
19.57
52W High
37.79
52W Low
9.98
Volume
1,095,711
Avg. Volume
1,889,529
Mkt Cap
1.36B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19FebExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.67
-0.44
-0.22
0.01
Expected EPS
-0.090816
Actual EPS
N/A

Financials

-10.21%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.88BRevenue
-192.05MNet Income

Analyst Ratings

$23.60Average Price Target
The highest estimate is 55.00.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TNDM. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Dexcom
DXCM
Mkt Cap22.71B
Dexcom produces continuous glucose monitoring systems, directly competing in the diabetes management space with Tandem's insulin pumps.
Insulet
PODD
Mkt Cap22.03B
Insulet Corporation offers the Omnipod, an insulin management system that competes with Tandem's insulin pump products.
Medtronic
MDT
Mkt Cap116.33B
Medtronic is a major player in the diabetes care market, offering insulin pumps and continuous glucose monitoring systems that compete with Tandem's offerings.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories produces the FreeStyle Libre, a continuous glucose monitoring system, competing in the broader diabetes management market.
Senseonics
SENS
Mkt Cap287.64M
Senseonics Holdings offers the Eversense CGM system, a direct competitor in the continuous glucose monitoring market.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific, through its life sciences solutions, indirectly competes in the diabetes care market by providing technologies and supplies that support diabetes research and diagnostics.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is a leading global healthcare company that, while primarily known for its diabetes medications, also invests in diabetes care devices and solutions, positioning it as a broader competitor.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is involved in diabetes care through its insulin and glucose monitoring solutions, making it a competitor in the diabetes management space.
Baxter International
BAX
Mkt Cap9.49B
Baxter International offers medical devices that, while not directly competing in the insulin pump or CGM markets, provide various healthcare solutions that can be used in diabetes care.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its medical devices and pharmaceutical segments, has interests in the diabetes market, making it a broader competitor in the healthcare space for diabetes management.

About

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Show more...
CEO
Mr. John F. Sheridan
Employees
2650
Country
US
ISIN
US8753722037

Listings

0 Comments

Share your thoughts

FAQ

What is Tandem Diabetes Care stock price today?
The current price of TNDM is $20.09 USD — it has increased by +1.01% in the past 24 hours. Watch Tandem Diabetes Care stock price performance more closely on the chart.
What is Tandem Diabetes Care stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tandem Diabetes Care stocks are traded under the ticker TNDM.
Is Tandem Diabetes Care stock price growing?
TNDM stock has fallen by -0.3% compared to the previous week, the month change is a -6.77% fall, over the last year Tandem Diabetes Care has showed a -44.81% decrease.
What is Tandem Diabetes Care market cap?
Today Tandem Diabetes Care has the market capitalization of 1.36B
When is the next Tandem Diabetes Care earnings date?
Tandem Diabetes Care is going to release the next earnings report on February 19, 2026.
What were Tandem Diabetes Care earnings last quarter?
TNDM earnings for the last quarter are -0.31 USD per share, whereas the estimation was -0.33 USD resulting in a +4.98% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tandem Diabetes Care revenue for the last year?
Tandem Diabetes Care revenue for the last year amounts to 1.88B USD.
What is Tandem Diabetes Care net income for the last year?
TNDM net income for the last year is -192.05M USD.
How many employees does Tandem Diabetes Care have?
As of February 03, 2026, the company has 2,650 employees.
In which sector is Tandem Diabetes Care located?
Tandem Diabetes Care operates in the Health Care sector.
When did Tandem Diabetes Care complete a stock split?
The last stock split for Tandem Diabetes Care was on October 10, 2017 with a ratio of 1:10.
Where is Tandem Diabetes Care headquartered?
Tandem Diabetes Care is headquartered in San Diego, US.